377 related articles for article (PubMed ID: 20648928)
1. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
Steinmetz T; Tschechne B; Harlin O; Klement B; Franzem M; Wamhoff J; Tesch H; Rohrberg R; Marschner N
Ann Oncol; 2013 Feb; 24(2):475-482. PubMed ID: 23071262
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
Naqash A; Ara R; Bader GN
BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China.
Jin J; Ran Z; Noseda E; Roubert B; Marty M; Mezzacasa A; Göring UM
Front Med; 2024 Feb; 18(1):98-108. PubMed ID: 37897561
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
6. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia.
Korczowski B; Farrell C; Falone M; Blackman N; Rodgers T
Pediatr Res; 2023 Oct; 94(4):1547-1554. PubMed ID: 37208431
[TBL] [Abstract][Full Text] [Related]
8. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE; Angerosa M
Drug Des Devel Ther; 2014; 8():2475-91. PubMed ID: 25525337
[TBL] [Abstract][Full Text] [Related]
9. The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD - the exploratory randomized controlled double-blind ExplorIRON-CKD study.
Kassianides X; Bhandari S
BMC Nephrol; 2024 Feb; 25(1):54. PubMed ID: 38347520
[TBL] [Abstract][Full Text] [Related]
10. Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.
Cirillo L; Somma C; Allinovi M; Bagalà A; Ferro G; Di Marcantonio E; Bellelli S; Dallari LA; Ballo P; Dattolo PC
Sci Rep; 2021 Apr; 11(1):7463. PubMed ID: 33811227
[TBL] [Abstract][Full Text] [Related]
11. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis.
Rogozińska E; Daru J; Nicolaides M; Amezcua-Prieto C; Robinson S; Wang R; Godolphin PJ; Saborido CM; Zamora J; Khan KS; Thangaratinam S
Lancet Haematol; 2021 Jul; 8(7):e503-e512. PubMed ID: 34171281
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.
Aksan A; Zepp F; Anand S; Stein J
Eur J Pediatr; 2022 Nov; 181(11):3781-3793. PubMed ID: 36056175
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study.
Dottori L; Corleone Tsar'kov D; Dilaghi E; Pivetta G; Scalamonti S; Ligato I; Esposito G; Annibale B; Lahner E
Nutrients; 2023 Sep; 15(19):. PubMed ID: 37836482
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of ferric carboxymaltose (iv) versus iron sucrose (iv) in treatment of iron deficiency anaemia in pregnancy: A systematic review and meta-analysis.
Srimathi G; Revathy R; Bagepally BS; Joshi B
Indian J Med Res; 2024 Jan; 159(1):62-70. PubMed ID: 38439125
[TBL] [Abstract][Full Text] [Related]
16. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
[TBL] [Abstract][Full Text] [Related]
17. Protocol for a multicentre, parallel-group, open-label randomised controlled trial comparing ferric carboxymaltose with the standard of care in anaemic Malawian pregnant women: the REVAMP trial.
Mwangi MN; Mzembe G; Moya E; Braat S; Harding R; Robberstad B; Simpson J; Stones W; Rogerson S; Biselele K; Chinkhumba J; Larson L; Ataíde R; Phiri KS; Pasricha SR
BMJ Open; 2021 Nov; 11(11):e053288. PubMed ID: 34815287
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction.
Drozd MD; Tkaczyszyn M; Kasztura M; Węgrzynowska-Teodorczyk K; Flinta I; Banasiak W; Ponikowski P; Jankowska EA
Cardiol J; 2024; 31(2):300-308. PubMed ID: 37853824
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
20. One-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Özden Ş; Tepetam FM; Atik Ö
Int Arch Allergy Immunol; 2024; 185(5):449-455. PubMed ID: 38272014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
